Abstract
Background
To evaluate contrast sensitivity (CS) using Pelli-Robson charts after intravitreal ranibizumab (IVR) (Lucentis, Novartis, Basel, Switzerland) or bevacizumab (IVB) (Avastin, Genentech, South San Francisco, California, USA) in eyes with myopic choroidal neovascularization (mCNV).
Methods
A retrospective review was performed of 17 consecutive patients treated with IVR (n = 10; 0.5 mg) or IVB (n = 7; 1.25 mg) for mCNV from July, 2006 with follow-ups through September, 2009. Re-treatment was performed at monthly or longer intervals if there was fluorescein leakage in fluorescein angiogram (FAG) and or apparent subretinal fluid in optical coherence tomography (OCT) persisted.
Results
CS improved by a mean of one letter at 1 month (n = 17; p = 0.32), four letters at 3 months (n = 17; p = 0.02), four letters at 6 months (n = 15; p = 0.01), five letters at 9 months (n = 14; p = 0.04) and six letters at 12 months (n = 13; p = 0.03). The mean number of IVR/IVB was 1.6/1.6, 2.6/2.3, 3.1/3.2, 4.1/4.2 and 4.5/4.6 at 1 month, 3 months, 6 months, 9 months, and 12 months, respectively.
Conclusions
Improvements in Pelli-Robson CS scores were observed during the first year after IVR/IVB in eyes with mCNV.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arden GB (1978) The importance of measuring contrast sensitivity in case of visual disturbance. Br J Ophtalmol 62:198–209
Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244
Elliott DB, Hurst MA, Weatherill J (1990) Comparing clinical tests of visual function in cataract with patient’s perceived visual disability. Eye 4:712–717
Haegerstrom-Portnoy G, Schneck ME, Lott LA, Brabyn JA (2000) The relation between visual acuity and other spatial vision measures. Optom Vis Sci 77:653–662
Kuyk T, Elliott JL (1999) Visual factors and mobility in persons with age-related macular degeneration. J Rehabil Res Dev 36:303–312
Marron JA, Bailey IL (1982) Visual factors and orientation-mobility performance. Am J Optom Physiol Opt 59:413–426
Mones J, Rubin GS (2005) Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularization due to age-related macular degeneration. Eye 19:1142–1150
Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, Tokoro T, Mocjizuki M (2003) Patchy atrophy and lacquer cracks predispose to development of choroidal neovascularization in pathological myopia. Br J Ophtalmol 87:570–573
Owsley C (2003) Contrast Sensitivity. Ophtalmol Clin North Am 16:171–177
Rubin GS (1988) Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vis Sci 2:169–177
Rubin GS, Roche KB, Prasado-Rao P, Fried LP (1994) Visual impairment and disability in older adults. Optom Vis Sci 71:750–760
Rubin GS, Bandeen-Roche K, Huang GH, Munoz B, Schein OD, Fried LP, West SK (2001) The association of multiple visual impairments with self report visual disability: SEE project. Invest Ophthalm Vis Sci 42:64–72
Conflicts of interest
The authors have no conflict of interests to declare.
Financial support
No financial support was provided for this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moussa, S., Ansari-Shahrezaei, S., Smretschnig, E. et al. Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 248, 1087–1090 (2010). https://doi.org/10.1007/s00417-010-1341-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-010-1341-x